ORGANIC
LETTERS
2007
Vol. 9, No. 15
2767-2770
CuI-Mediated Cross-Coupling of Aryl
Halides with Oximes: A Direct Access
to O-Aryloximes
Prithwiraj De, Nonappa, Komala Pandurangan, Uday Maitra,*,† and Steve Wailes*,‡
Department of Organic Chemistry, Indian Institute of Science, Bangalore 560 012,
India, and Syngenta Ltd., Jealott’s Hill International Research Centre, Bracknell,
Berkshire RG42 6EY, U.K.
Received April 24, 2007
ABSTRACT
The first Cu-catalyzed cross-coupling of aromatic oximes and haloarenes is reported. This one-step formation of the
access to a range of oxime ethers in good to moderate yields.
dN−O−Ar linkage gives
O-Aryloxime ethers are attractive synthetic targets because
of their considerable application potential in medicinal and
bioorganic chemistry. For example, some benzisoxazole
derivatives have been reported as inhibitors of protein
chaperone Hsp 901a and monoamine oxidase.1b Some others
show good cytokinin-like1c and neuroleptic1d activities.
1,2-Oxazines are NO-prodrugs2a and show anticholinesterase
activity,2b and molecules like 6-aryl-3,6-dihydro-1,2-oxazines
are mGluR1 receptor antagonists.2c Recently, some bisaryl-
oxime ethers were found to be potent inhibitors of trans-
thyratin amyloid fibril formation.3 Despite their potential
applications, the synthesis of O-aryloxime ethers remains a
challenge. As a result, there is a need to develop a general
synthetic method for O-aryloxime ethers.
Available literature approaches for the preparation of
O-aryl oxime ethers essentially deal with the reaction of the
sodium salt of an oxime with fluorobenzene derivatives,4a
reaction of aldehydes/ketones with O-phenylhydroxylamine,3
or reaction of oximes with aryl nitrates4b/diazonium salts.4c
However, these procedures lack generality and cannot be
used with other haloarenes such as iodo- and bromobenzenes.
A serendipitous intramolecular coupling of 2-iodo-2′,5-
dichlorobenzophenone oxime (1) to yield the corresponding
benzisooxazole derivative (1a) under standard Sonogashira
conditions was reported in the literature.5 This formed the
basis for our exploratory work to develop a simple and
general method for the synthesis of O-aryloxime ethers.
† Indian Institute of Science.
‡ Syngenta Ltd.
(1) (a) Mailliet, P.; Ruxer, J. M.; Thompson, F.; Luc, C. C. New 3-aryl-
1,2-benzisoxazole derivatives, compositions containing them and their use
for treating cancer. French Patent FR 288236, August 25, 2006. (b) Yoshimi,
K.; Kozuka, M.; Sakai, J.; Lizawa, T.; Shimizu, Y.; Kaniko, I.; Kojima,
K.; Iwata, N. Jpn. J. Pharmacol. 2002, 88, 174. (c) Ricci, A.; Carra, A.;
Torelli, A.; Maggiali, C. A.; Vicini, P.; Zani, F.; Branca, C. Plant Growth
Regul. 2001, 34, 167. (d) Strupczewski, J. T.; Allen, R. C.; Gardner, B. A.;
Schmid, B. L.; Stache, U.; Glamkowski, E. J.; Jones, M. C.; Ellis, D. B.;
Huger, F. P.; Dunn, R. W. J. Med. Chem. 1985, 28, 761.
(2) (a) Chakrapani, H.; Toone, E. J. Abstracts of Papers. 230th ACS
National Meeting; Washington, DC, Aug 28-Sept 1, 2005; American
Chemical Society: Washington, DC, 2005; MED-414. (b) Yu, Q-s; Zhu,
X.; Holloway, H. W.; Whittaker, N. F.; Brossi, A.; Greig, N. H. J. Med.
Chem. 2002, 45, 3684. (c) Clark, B. P.; Harris, J.; Richard; K.; Ann, E.
Preparation of 6-aryl-3,6-dihydro-1,2-oxazines as mGluR1 receptor antago-
nists. UK Patent WO 2000026199, May 11, 2000.
(3) (a) Johnson, S. M.; Petrassi, H. M.; Palaninathan, S. K.; Mohamed-
mohaideen, N. N.; Purkey, H. E.; Nichols, C.; Chiang, K. P.; Walkup, T.;
Sacchettini, J. C.; Sharpless, K. B. and Kelly, J. W. J. Med. Chem. 2005,
48, 1576. (b) Blake, J. A.; Pratt, D. A; Lin, S.; Walton, J. C.; Mulder, P.;
Ingold, K. U. J. Org. Chem. 2004, 69, 3112.
(4) (a) Mooradian, A.; Dupont, P. E. J. Heterocycl. Chem. 1967, 4, 441.
(b) Jacob, B. B. Synthesis 1975, 782. (c) Nesynov, E. P. Zh. Org. Khim.
1976, 12, 1955.
(5) Coffen, D. L.; Schaer, B.; Bizzarro, F. T.; Chung, J. B. J. Org. Chem.
1984, 49, 296. Reaction conditions: (PPh3)2PdCl2-CuI/Et3N-CH2Cl2.
10.1021/ol0709578 CCC: $37.00
© 2007 American Chemical Society
Published on Web 06/20/2007